The development of novel therapeutic agents is a cornerstone of modern medicine, particularly in addressing chronic and widespread conditions like cardiovascular diseases. Among the key compounds driving innovation in this sector is Ivabradine, a drug renowned for its ability to selectively reduce heart rate. At the heart of Ivabradine's synthesis lies a crucial chemical intermediate: 4,5-Dimethoxy-1-benzocyclobutenecarbonitrile (CAS 35202-54-1). This article delves into the significance of this intermediate and its role in enabling advanced cardiovascular therapies.
Understanding Ivabradine and its Mechanism
Ivabradine is primarily prescribed for patients suffering from symptomatic chronic stable angina pectoris who have a normal sinus rhythm but are intolerant to or contraindicated for beta-blockers. Its unique mechanism of action involves selectively inhibiting the If current in the sinoatrial node, thereby reducing heart rate without affecting myocardial contractility or blood pressure. This targeted approach offers a valuable therapeutic option for managing angina symptoms and improving quality of life.
4,5-Dimethoxy-1-benzocyclobutenecarbonitrile: The Essential Building Block
The journey from basic chemicals to a complex API like Ivabradine involves a series of precise chemical transformations. 4,5-Dimethoxy-1-benzocyclobutenecarbonitrile serves as a fundamental precursor in this synthesis pathway. Its specific structural features, including the benzocyclobutane ring system and the methoxy and nitrile functional groups, provide the necessary chemical architecture that is elaborated upon through subsequent reactions to form the final Ivabradine molecule. The quality and purity of this intermediate, therefore, have a direct impact on the efficiency of the synthesis and the purity of the final drug product.
Sourcing High-Quality Intermediate from a Trusted Manufacturer
Pharmaceutical companies require a consistent and reliable supply of high-purity intermediates to maintain their production schedules and ensure the quality of their medications. For 4,5-Dimethoxy-1-benzocyclobutenecarbonitrile, sourcing from experienced manufacturers is paramount. NINGBO INNO PHARMCHEM CO.,LTD. specializes in producing high-grade pharmaceutical intermediates, including CAS 35202-54-1. With an assay of ≥98.0% and stringent quality controls, we ensure that our product meets the demanding standards required for drug synthesis. As a leading manufacturer and supplier in China, we are committed to providing reliable access to this vital compound, enabling the continued production and availability of Ivabradine for patients worldwide.
By understanding the critical role of intermediates like 4,5-Dimethoxy-1-benzocyclobutenecarbonitrile, pharmaceutical professionals can make informed decisions regarding their procurement. Partnering with a reputable supplier ensures that the journey from raw material to life-saving therapy is robust, efficient, and of the highest quality. We encourage you to inquire about buying this key intermediate and discover how our commitment to excellence can support your pharmaceutical endeavors.
Manufacturing Facilities






Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.